Reports
Global Cancer Cachexia Market: By Therapeutics: Progestogens, Corticosteroids, Combination Therapy, Others; By Mechanism of Action: Appetite Stimulators, Others; By Distribution Channel; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Cancer Cachexia Market Outlook
The global cancer cachexia market is expected to grow at a CAGR of 4.7% during the period 2023-2028.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Cancer Cachexia Market Likely to be Driven by Rising Number of Cachexia Cases and Advancements in Treatment Systems
The global market for cancer cachexia is expected to be driven by rising instances of cachexia and developments in modern treatment systems. North America, Europe and Japan are expected to be key markets. Cases of cachexia are growing and presently, the condition affects nearly 1 percent of all patients. Recent years have witnessed increased understanding of the multifarious nature of cachexia, in particular, the function of inflammatory mediators and anabolic and catabolic imbalances. While many treatment methodologies have not been able to clear phase III clinical trials despite initial promise, the ghrelin receptor agonist anamorelin has delivered initial results.
Cachexia is a serious outcome of a variety of chronic conditions, and associated with a poor quality of life. In last-stage chronic heart failure, the occurrence of cachexia ranges from 5–15 percent; in cases of advanced cancer, the incidence of cachexia lies between 50–80 percent. Many people with chronic renal disease, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis develop cachexia as they near the end of their lives. Cachectic syndrome is a key source of morbidity and mortality in cancer patients. Cancer cachexia has also been linked to decreased chemotherapeutic efficacy, increased adverse effects, and discontinuation of treatment. Progressive cachexia signals poor prognosis with a shorter survival time, and explains close to 20 percent of all cancer deaths. If there is weight loss of 10 percent or more within a period of 6 months, it may indicate presence of cachexia. There is a direct relation between survival of cancer patients and rate and amount of weight loss.
Cachectic syndrome is described to have three stages - precachexia, cachexia, and refractory cachexia. In the precachectic stage, indications such as such as weight loss (less than 5 percent), anorexia, and impaired glucose tolerance appear. Advancement to cachexia depends on several factors including systemic inflammation, type and stage of cancer, low food intake, and response to treatment. In refractory cachexia, active weight loss management is rendered almost impossible due to active catabolism or presence of cachectic factors. Patients experiencing acute muscle wasting are not likely to gain from treatments aimed at achieving lean tissue and function. In this phase, therapy seeks to mitigate symptoms and reduce distress rather than prolong life.
Combination Therapies Involving Novel Medicinal Agents Show Promise; New Drugs Expected to Stimulate Market
At present, cancer cachexia is incurable. Current therapies for cachexia entail a multidisciplinary approach; combination therapy including diet adjustments and exercise (where possible) has been integrated with new medicinal agents such as Megestrol acetate, medroxyprogesterone, ghrelin, and omega-3-fatty acid, among others. These treatments have been reported to yield better survival rates and quality of life. Advancements in treatment systems and promise shown by under-trial drugs are expected to boost the market.
In 2021, Helsinn, a Swiss pharmaceutical group engaged in the production of high-quality cancer care and rare disease products, announced the first launch of Adlumizo (anamorelin) to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer in Japan, through Ono Pharmaceutical, its partner firm. Adlumizo (anamorelin), approved by the Japanese Health Authorities, has been shown to be effective in increasing body weight, muscle mass, and appetite in cancer cachexia patients.
AV-380 by AVEO is first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). Preclinical data suggest that inhibition of GDF15 leads to a switch from catabolism to anabolism, which indicates that GDF15 inhibition with AV-380 may reverse the effects of cachexia. As of 2022, AVEO Oncology completed enrolment in its phase I trial in Cachexia (In volunteers) in USA (Parenteral) (NCT04815551), and planned to commence a phase Ib trial in Cancer in mid-2022.
Global Cancer Cachexia Market Segmentation
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By therapeutics, the market is divided into:
- Progestogens
- Corticosteroids
- Combination Therapy
- Others
By mechanism of action, the market is classified into:
- Appetite Stimulators
- Weight Loss Stabilizers
By distribution channel, the market is segmented into:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By region, the market is classified into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Industry Players in the Global Cancer Cachexia Market
The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Merck & Co., Inc.
- Aphios Corporation
- Helsinn Healthcare SA
- AVEO Pharmaceuticals, Inc.
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Therapeutics, Mechanism of Action, Distribution Channel, Region |
| Breakup by Therapeutics | Progestogens, Corticosteroids, Combination Therapy, Others |
| Breakup by Mechanism of Action | Appetite Stimulators, Weight Loss Stabilizers |
| Breakup by Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Merck & Co., Inc., Aphios Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Cancer Cachexia Market Analysis
8.1 Key Industry Highlights
8.2 Global Cancer Cachexia Historical Market (2018-2022)
8.3 Global Cancer Cachexia Market Forecast (2023-2028)
8.4 Global Cancer Cachexia Market by Therapeutics
8.4.1 Progestogens
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Corticosteroids
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Combination Therapy
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Others
8.5 Global Cancer Cachexia Market by Mechanism of Action
8.5.1 Appetite Stimulators
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Weight Loss Stabilizers
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.6 Global Cancer Cachexia Market by Distribution Channel
8.6.1 Hospital Pharmacy
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Retail Pharmacy
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Online Pharmacy
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.7 Global Cancer Cachexia Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Merck & Co., Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Aphios Corporation
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Helsinn Healthcare SA
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 AVEO Pharmaceuticals, Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Ono Pharmaceutical Co., Ltd.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Pfizer Inc.
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Cancer Cachexia Market: Key Industry Highlights, 2017 and 2021
2. Global Cancer Cachexia Historical Market: Breakup by Therapeutics (USD Million), 2018-2022
3. Global Cancer Cachexia Market Forecast: Breakup by Therapeutics (USD Million), 2023-2028
4. Global Cancer Cachexia Historical Market: Breakup by Mechanism of Action (USD Million), 2018-2022
5. Global Cancer Cachexia Market Forecast: Breakup by Mechanism of Action (USD Million), 2023-2028
6. Global Cancer Cachexia Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
7. Global Cancer Cachexia Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
8. Global Cancer Cachexia Historical Market: Breakup by Region (USD Million), 2018-2022
9. Global Cancer Cachexia Market Forecast: Breakup by Region (USD Million), 2023-2028
10. North America Cancer Cachexia Historical Market: Breakup by Country (USD Million), 2018-2022
11. North America Cancer Cachexia Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Europe Cancer Cachexia Historical Market: Breakup by Country (USD Million), 2018-2022
13. Europe Cancer Cachexia Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Asia Pacific Cancer Cachexia Historical Market: Breakup by Country (USD Million), 2018-2022
15. Asia Pacific Cancer Cachexia Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Latin America Cancer Cachexia Historical Market: Breakup by Country (USD Million), 2018-2022
17. Latin America Cancer Cachexia Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Middle East and Africa Cancer Cachexia Historical Market: Breakup by Country (USD Million), 2018-2022
19. Middle East and Africa Cancer Cachexia Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Global Cancer Cachexia Market Structure
Key Questions Answered in the Report
The global cancer cachexia market is projected to grow at a CAGR of 4.7% between 2023 and 2028.
The major drivers of the market include the neglected requirement for the therapy of cancer cachexia in creating economies, continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare.
The rising instances of cachexia and developments in modern treatment systems are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
On the basis of therapeutics, the market is divided into progestogens, corticosteroids, and combination therapy, among others.
Based on mechanism of action, the market is divided into appetite stimulators and weight loss stabilisers.
The several distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy.
The major players in the industry are Merck & Co., Inc., Aphios Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others.
Analyst Review
The global cancer cachexia market was driven by the rising instances of cachexia and developments in modern treatment systems in the historical period. Aided by continuous clinical trials in oncology and expanding mindfulness among individuals and healthcare experts, the market is expected to witness further growth in the forecast period of 2023-2028, growing at a CAGR of 4.7%.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. On the basis of therapeutics, the market is divided into progestogens, corticosteroids, and combination therapy, among others. Based on mechanism of action, the market is divided into appetite stimulators and weight loss stabilisers. The several distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy. The major regional markets for cancer cachexia market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The major players in the industry are Merck & Co., Inc., Aphios Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER